Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced it will host an investor presentation on October 21, 2026, at 9 a.m. EDT. The event will highlight the company's proprietary NSA candidates: HLP003, in Phase 3 development for the adjunctive treatment of major depressive disorder (MDD), and HLP004, in Phase 2 development for generalized anxiety disorder (GAD). The presentation will also feature perspectives from key opinion leaders on the evolving depression and anxiety treatment landscape, followed by a question-and-answer session with Helus Pharma executives. A live webcast will be accessible through the company's website, with a replay available afterward.
The announcement comes as mental health conditions like depression and anxiety continue to impose a significant global burden, with many patients not achieving adequate relief from existing therapies. Helus Pharma's NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, potentially offering durable improvements. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for adjunctive MDD treatment, underscoring its potential to address a large unmet need. If successful, these therapies could expand treatment options for millions and reshape the standard of care.
Helus Pharma™, the commercial operating name of Cybin Inc., was founded in 2019 and operates in Canada, the United States, the United Kingdom, and Ireland. The company is committed to helping minds heal by developing proprietary NSAs intended to address depression, anxiety, and other mental health conditions. In addition to HLP003 and HLP004, Helus Pharma has an extensive research portfolio of investigational NSAs. For more information, visit www.helus.com.
The full press release is available at https://ibn.fm/akaNj. Investors can find the latest news and updates in the company's newsroom at Helus Pharma.
This article has been disseminated on behalf of Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP) and may include paid advertising. BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform provides access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
For full terms of use and disclaimers applicable to all content provided by BioMedWire, visit https://www.BioMedWire.com/Disclaimer. The original source of this content is www.BioMedWire.com.
